Influence of a Single Dose Dexamethasone on the Time Course of Neuromuscular Blockade of Rocuronium
This study has been completed.
Information provided by (Responsible Party):
First received: January 31, 2013
Last updated: February 1, 2013
Last verified: January 2013
The aim of the present study is to compare the time course of a neuromuscular block in patients receiving dexamethasone 8 mg in order to reduce postoperative nausea or vomiting several hours before surgery with patients receiving the drug immediately before induction of anaesthesia and patients without a dexamethasone prophylaxis. The primary end point is the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9.
Neuromuscular Block, Dexamethasone
Neuromuscular Block, Recovery
||Observational Model: Case-Crossover
Time Perspective: Prospective
Primary Outcome Measures:
- the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9. [ Time Frame: one hour ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2013 (Final data collection date for primary outcome measure)
dexamethasone during induction of anesthesia
no dexamethasone during measurements
dexamethasone before induction of anesthesia
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
patients of a primary care clinic undergoing elective gynecologic abdominal surgery
- patients aged 18 to 65 years,
- American Society of Anesthesiologists Physical Status I or II,
- 50-90 kg body weight,
- undergoing elective laparoscopic gynaecological surgery in general anaesthesia necessitating intraoperative neuromuscular blockade.
- expected difficulties with endotracheal intubation (history of difficult intubation,
- reduced opening of the mouth (< 2cm), and Mallampati Score of 4),
- increased risk of pulmonary aspiration (gastrooesophageal reflux, full stomach, intestinal obstruction),
- known allergies to the drugs tested,
- neuromuscular disorders,
- intake of drugs affecting neuromuscular blockade, such as furosemide, magnesium or cephalosporins,
- hepatic-or renal insufficiency.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01782820
|Dormagen, Germany, D-51375 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 31, 2013
||February 1, 2013
||Germany: Ethics Commission
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 10, 2014
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Molecular Mechanisms of Pharmacological Action